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Abstract
Bovine spongiform encephalopathy (BSE) is a fatal, transmissible, neurodegenerative disease of cattle. To date, the disease
process is still poorly understood. In this study, brain tissue samples from animals naturally infected with BSE were
analysed to identify differentially regulated genes using Affymetrix GeneChip Bovine Genome Arrays. A total of 230 genes
were shown to be differentially regulated and many of these genes encode proteins involved in immune response,
apoptosis, cell adhesion, stress response and transcription. Seventeen genes are associated with the endoplasmic
reticulum (ER) and 10 of these 17 genes are involved in stress related responses including ER chaperones, Grp94 and
Grp170. Western blotting analysis showed that another ER chaperone, Grp78, was up-regulated in BSE. Up-regulation of
these three chaperones strongly suggests the presence of ER stress and the activation of the unfolded protein response
(UPR) in BSE. The occurrence of ER stress was also supported by changes in gene expression for cytosolic proteins, such as
the chaperone pair of Hsp70 and DnaJ. Many genes associated with the ubiquitin-proteasome pathway and the
autophagy-lysosome system were differentially regulated, indicating that both pathways might be activated in response
to ER stress. A model is presented to explain the mechanisms of prion neurotoxicity using these ER stress related
responses. Clustering analysis showed that the differently regulated genes found from the naturally infected BSE cases
could be used to predict the infectious status of the samples experimentally infected with BSE from the previous study
and vice versa. Proof-of-principle gene expression biomarkers were found to represent BSE using 10 genes with 94%
sensitivity and 87% specificity.
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Introduction
Transmissible spongiform encephalopathies (TSEs), also
termed prion diseases, are fatal, neurodegenerative diseases
including Creutzfeldt-Jakob disease (CJD) in humans, scrapie in
goats and sheep and bovine spongiform encephalopathy (BSE) in
cattle [1,2,3,4]. The infectious agent of these diseases is thought
to be an abnormally folded isoform (PrPSc) of the cellular prion
protein (PrPC) and it is further thought that the accumulation
of the misfolded prion protein leads to disease [1]. PrPSc is
characterized by a high b-sheet content and resistance to
protease treatment. In addition to the accumulation of PrPSc, the
pathological features of prion diseases in the brain of affected
subjects include neuronal cell loss and vacuolation. Prion
diseases have long incubation periods prior to the onset of
clinical signs.
BSE was first discovered in 1986 [5] and became a major
epidemic in the UK, peaking in 1992; to date more than 185,000
cases have been recorded. It is thought to be caused by
contaminated meat and bone meal, a dietary supplement for
cattle [6]. The BSE strain has also most probably crossed the
species barrier to humans and has produced variant CJD [7]. The
mean incubation period of BSE in cattle is estimated at about 5
years [3]. The clinical signs are: difficulties in locomotion and
behavioural changes. The neuropathology of BSE is characterized
by the lesions mainly found in the brain stem where vacuolar
changes are found in neurons and the neuropil [5]. However,
apoptosis plays a very limited role in neuronal loss in BSE [8].
In recent years atypical bovine spongiform encephalopathy has
been identified [9,10]. In these cases the distribution of PrPSc in
the animal differs from that of BSE; there is less PrPSc
accumulation in the brain stem and the biochemical signature of
PrPSc is different.
The pathogenesis of BSE is still poorly understood. In a
previous gene expression study using brain tissue samples from
cattle experimentally infected with BSE, we have demonstrated
that the largest number of differentially regulated genes is
detected at 21 months post inoculation, suggesting that there are
many pathogenic processes in the animal brain even prior to
the detection of infectivity in the CNS of these orally dosed
cattle [11]. Moreover, a set of differentially regulated genes
could be used to predict the infectious status of preclinical
samples.
To further understand the pathogenesis of BSE and to explore
the possibility of using gene expression profiles as biomarkers, we
analysed brainstem RNA samples from confirmed naturally
infected cases of BSE (field cases) in cattle and from healthy
controls.
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Results
Identification of differentially regulated genes in the BSE
field case samples
The expression of genes in the brain of naturally infected BSE
samples was compared with negative controls. In order to identify
differentially regulated genes in BSE, the following stringent
conditions were set with two filters: 2 fold change and one-way
ANOVA with the p value being 0.05. 409 probe sets (a technical
term that describes a transcript on the microarray) were identified
as differentially regulated between the BSE infected (n= 14) and
negative (n = 12) samples. After removal of duplications, 230 genes
were identified and these genes are listed in Table 1 and the
unannotated probe sets are listed in Table S1.
Only 18 genes (8%) were down-regulated and 212 (92%) genes
were up-regulated after the repeated or un-annotated probe sets
were removed (Table 1). Each step of filtering was re-examined to
determine the number of up and down-regulated genes. The 2 fold
change filter yielded 2138 probe sets: 792 (37%) of them were
down-regulated in BSE field cases and 1346 (63%) probe sets were
up-regulated. When the 2 fold change and 1-way ANOVA filters
were combined, 409 probe sets were selected: 366 (89%) of them
up-regulated and 43 (11%) probe sets down-regulated. Therefore,
the up-regulated genes were increased in percentage after the
ANOVA filter.
The largest functional group amongst the 230 identified genes
was the genes involved in transport (39 genes), followed by the
membrane protein group (25 genes), the metabolism group (20
genes) and the DNA and RNA binding group (19 genes; Table 1).
The maximal increase was 5.75 fold for Myosin head domain
containing 1 and the maximal decrease was 4.92 fold for OCIA
domain containing 1.
Many genes in Table 1 were linked to prion diseases in previous
studies, such as cathepsin D [12], cathepsin B [13], Inositol 1,4,5-
triphosphate receptor [13], apolipoprotein D [13], vimentin
[12,13], heat shock protein 70 [14], transferrin [15], reticulum 1
[16], reticulum 3 [17], a gene similar to solute carrier family 25
[13], CD9 [13,18], vacuolar protein sorting 11 homolog [11] and
DnaJ [11].
The microarray data were validated and confirmed by
quantitative PCR using 5 genes: CD47, DnaJ, Hsp70 (up-
regulated) and KCNB2, TNFRSF5 (down-regulated) (Figure S1).
Clustering analysis using the 409 probe sets showed that the
samples were divided into two groups, Group A contained only
negative control samples, while Group B contained all the BSE
infected samples plus one negative control sample (Figure 1). This
analysis confirmed that the samples of BSE and controls were
relatively homogeneous amongst themselves with regard to the
genes defined as differentially regulated.
ER stress is implicated in disease pathogenesis
There were 17 differentially regulated genes whose products are
associated with the ER (in bold in Table 1). Upregulation of
glucose-regulated protein 94 (Grp94/gp96; ER stress response
chaperone) and glucose-regulated protein 170 (Grp170/Orp150;
ER stress response chaperone) suggests ER stress [19] as both of
them are also known as ER stress markers (Table 1) [20].
Disturbance in the ER leads to ER stress which can be caused by
accumulation of unfolded proteins and by changes in calcium
homeostasis within the ER [21]. In BSE, many other stress related
genes whose products are located in the ER were also up-
regulated, such as Inositol 1,4,5-triphosphate receptor (IP3-R; ER
calcium-depletion stress) [22]. reticulon 1 (ER stress induced
apoptosis) [23], reticulon 3 (ER stress response) [24], reticulon 4
(ER stress induced apoptosis) [25], CDC91 cell division cycle 91-
like (Gab1; oxidative stress) [26], procollagen-proline, 2-oxogluta-
rate 4-dioxygenase (P4HA1; ER stress response) [27], LAG1
homolog, ceramide synthase 2 (CerS2; inhibition of the unfolded
protein response and autophagy) [28] and signal sequence
receptor, alpha (SSR1 calcium binding) [29] (Table 1). In this
study, both cytosolic chaperones Hsp70 and DnaJ were also found
up-regulated (Table 1) and this chaperone pair is also induced by
ER stress [30]. Other ER stress related gene products in the
cytosol were: N-myc downstream regulated gene 1 (Ndrg1; ER
stress responsive) [31], aldo-keto reductase family 1, member B1
(Akr1b1; anti ER stress) [32], O-linked N-acetylglucosamine
(GlcNAc) transferase (anti ER stress) [33], transketolase (anti ER
stress) [34] and cyclin-dependent kinase 5 (Cdk5; Apoptosis in ER
stress) [35] (Table 1). These changes suggest the involvement of
ER stress during BSE pathogenesis.
In response to ER stress, the unfolded protein response (UPR) is
induced to restore cell function by reduction in newly translated
proteins entering into the ER, by an increase in the capacity for
protein folding [36]. If ER stress is prolonged, the UPR signaling
pathways also initiate apoptosis [36]. In BSE, up-regulation of
chaperones Grp94 and Grp170 suggests the induction of the UPR;
while up-regulation of CerS2 indicates the inhibition of the UPR.
To further explore the involvement of ER stress in the
pathogenesis of BSE, Western blotting analysis on two more ER
stress markers, Grp78 and Chop, was carried out. Grp78, is an ER
chaperone and also known as an ER stress master regulator; while
Chop is a transcription factor for induction of apoptosis, often up-
regulated in response to ER stress [36]. In BSE, the Grp78 protein
was up-regulated (Figure 2). Up-regulation of these ER chaper-
ones: Grp78, 94 and 170 indicates the presence of ER stress and
the activation of the UPR. The level of Chop was slightly
decreased (Figure 2) and this is consistent with the evidence that
apoptosis plays a very limited role in BSE [8].
Using the gene expression profiles as a biomarker to
represent BSE
In our previous BSE time course study, 205 differentially
regulated probe sets (corresponding to 114 genes) have been used
to show that preclinical animals at 45 months post inoculation
(mpi) cluster with cases positive for BSE and allowed the
prediction that they are indeed preclinical and close to developing
BSE [11]. The same 205 probes sets were used here in a clustering
analysis to classify the disease status of the samples from the BSE
field cases (Figure 3). These samples fell into two main groups:
Group A contained 11 positives and one negative, Group B
contained the remaining 11 negatives and three positives. This
analysis was therefore able to classify the samples according to
infection status with 78.5% (11/14) sensitivity and 92% (11/12)
specificity.
In a reverse analysis, the 409 probe sets identified in this study
were used for clustering the samples from the time course study
[11]. One group included the negatives, the samples from animals
6 mpi and 36 mpi and the other group contained the positives,
and the samples from 21, 27 and 39 mpi animals (Figure 4a). The
clustering was similar to the one derived with the 205 probe sets
from the time course study [11]. When these 409 probe sets were
used to predict the status of the preclinical animals at 45 mpi in
the time course study the clustering analysis grouped the individual
samples into two groups: one with all the negatives (n = 3) and
6 mpi samples (n = 3) and the other with all the positives (n = 3)
and 45 mpi samples (n = 2) (Figure 4b).
The analyses above indicate that either the genes from the time
course study or the field case samples could be used to predict the
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Table 1. Relative levels of differentially expressed genes of BSE.
Gene ID Gene Nams Fold p-value
change
Cell adhesion Bt.23129.3.S1 similar to Laminin gamma-1 chain precursor (Laminin B2 chain) 2.70 0.0209
Bt.2573.1.S1 CD9 antigen (p24) 3.61 0.0164
Bt.4817.2.S1 claudin 11 5.38 0.019
Bt.8382.2.S1 ras homolog gene family, member B 2.14 0.0119
Bt.11224.1.S1 similar to 85 kDa lysosomal sialoglycoprotein 2.83 0.0266
Bt.15742.1.S2 CD47 molecule 2.04 0.0316
Bt.18378.1.S1 similar to KIAA1014 protein 2.29 0.0401
Bt.4653.1.S2 platelet/endothelial cell adhesion molecule 3.57 0.0399
Apoptosis Bt.5250.1.S1 milk fat globule-EGF factor 8 protein 2.58 0.035
Bt.222.1.S1 crystallin, alpha B 2.07 0.0469
Bt.13130.1.S1 tumor necrosis factor receptor superfamily, member 5 22.33 0.0469
Bt.16079.1.S1 reticulon 3* 2.10 0.041
Bt.21430.1.S1 similar to Synovial apoptosis inhibitor 1, synoviolin 5.18 0.0237
Bt.16916.1.S1 TGF-beta inducible early growth response protein 2 2.24 0.028
Bt.23228.1.S1 Similar to Fas apoptotic inhibitory molecule 2 2.74 0.041
Bt.2408.1.S1 chemokine (C-C motif) ligand 2 23.07 0.0428
Bt.8220.1.A1 similar to transforming acidic coiled coil 1 2.21 0.0242
Immune Bt.9504.1.A1 putative MIP1-beta protein 24.55 0.0239
responses Bt.24900.1.S1 similar to T-cell immunomodulatory protein 2.2 0.0141
Bt.29761.1.S1 T-cell receptor beta chain variable segment 24.69 0.0172
Bt.26847.1.S1 linker for activation of T cells 22.75 0.0423
Bt.4060.1.S1 T-cell differentiation protein Mal 2.87 0.0109
Bt.4175.2.S1 similar to minor histocompatibility antigen 13 3.69 0.0467
Bt.3791.1.S1 basigin 2.11 0.0401
cell cycle & Bt.22534.1.S1 similar to peripheral myelin protein 22 2.69 0.0171
growth Bt.11059.1.S1 Putative tumor suppressor LUCA15) (G15 protein 2.85 0.0084
Bt.2214.1.S1 similar to prostacyclin-stimulating factor; PGI2-stimulating factor; PSF 2.09 0.0164
Bt.2220.2.A1 selenoprotein P, plasma, 1 2.45 0.0171
Bt.4750.1.S1 transketolase 2.04 0.0219
Bt.29157.1.A1 growth arrest-specific 2 like 1 22.58 0.0438
Bt.29718.2.A1 growth hormone receptor 24.46 0.0129
Bt.51.1.S1 cyclin-dependent kinase 5 3.60 0.049
Extracellular Bt.23250.6.A1 alpha-2-HS-glycoprotein 5.68 0.0249
Bt.28584.1.S1 canopy 3 homolog 3.97 0.0288
Bt.5313.1.S1 matrix metallopeptidase 2 2.90 0.0427
cell proliferation Bt.4529.1.S1 farnesyltransferase, CAAX box, beta 2.65 0.0119
& differentiation Bt.5224.1.S1 dihydropyrimidinase-like 2 2.52 0.0172
Bt.435.1.S1 TIMP metallopeptidase inhibitor 2 2.91 0.0069
Bt.1537.1.S1 N-myc downstream regulated gene 1 2.18 0.0261
Transport Bt.10135.1.A1 similar to solute carrier family 35, member A5 2.76 0.0138
Bt.13535.1.A1 similar to hippocampus abundant transcript-like 1 2.42 0.0289
Bt.15466.1.A1 unc-50 homolog 2.78 0.0475
Bt.26510.1.S1 Proteolipid protein 2.08 0.0264
Bt.23637.1.S1 adaptor-related protein complex 3, mu 1 subunit 2.08 0.0375
Bt.21740.1.S1 transmembrane emp24-like trafficking protein 10 2.14 0.0499
Bt.13583.1.A1 similar to ATP-binding cassette transporter G1 2.14 0.0484
Bt.903.1.S1 similar to choline transporter-like protein 1, splice 2.94 0.0052
Bt.21168.1.A1 synaptophysin-like 1 2.02 0.0201
A Transcriptome Study of BSE
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Gene ID Gene Nams Fold p-value
change
Bt.16001.1.S1 similar to sterol 27-hydroxylase 2.16 0.0272
Bt.3418.1.S1 mitochondrial carrier homolog 1 2.15 0.0447
Bt.15804.1.S1 similar to chloride channel protein 3 2.22 0.0175
Bt.20007.1.S1 ATP-binding cassette, sub-family C (CFTR/MRP), member 5 2.12 0.0471
Bt.21424.1.A1 similar to receptor Pit2 2.14 0.041
Bt.22735.1.S1 similar to synaptotagmin-like 2 2.27 0.022
Bt.2331.1.A1 similar to receptor activity-modifying protein 1 2.15 0.0145
Bt.23500.1.S1 secretory carrier membrane protein 4 2.23 0.024
Bt.23518.2.S1 similar to tetracycline transporter-like protein 2.07 0.0122
Bt.23606.1.S1 inositol 1,4,5-triphosphate receptor, type 1 3.53 0.0455
Bt.269.1.S1 ATPase, Ca++ transporting, type 2C, member 1 2.03 0.0312
Bt.26994.1.A1 potassium voltage-gated channel, Shal-related subfamily, member 2 23.54 0.0298
Bt.27129.1.S1 similar to solute carrier family 39 (zinc transporter), member 9 2.04 0.0335
Bt.3414.3.A1 HIV-1 Rev binding protein 2.12 0.0312
Bt.4335.1.S1 similar to protoporphyrinogen oxidase 3.57 0.0204
Bt.4430.1.S2 similar to vacuolar H+-ATPase subunit 2.09 0.0349
Bt.4977.1.S2 insulin-like growth factor 2 receptor 2.07 0.0399
Bt.5000.1.S1 coatomer protein complex, subunit gamma 2 2.00 0.0416
Bt.5293.1.S1 ATPase, H+ transporting, lysosomal 16 kDa, V0 subunit c 2.5 0.0428
Bt.5293.2.A1 proteolipid protein 1 2.4 0.0141
Bt.5336.1.A1 transferrin 3.22 0.0084
Bt.6096.1.S1 similar to Conserved oligomeric Golgi complex component 2 5.41 0.0171
Bt.7134.1.S2 glycolipid transfer protein 2.38 0.0143
Bt.8822.1.A1 similar to inward rectifier potassium channel Kir1.2 2.76 0.0203
Bt.9853.1.S1 similar to Solute carrier family 25 member 14 4.35 0.0324
Bt.26889.1.S1 solute carrier family 33 (acetyl-CoA transporter), member 1 2.11 0.039
Bt.4646.1.S1 solute carrier family 2 (facilitated glucose transporter), member 1 2.35 0.0171
Bt.3208.1.S1 DDHD domain containing 2 2.0 0.0306
Bt.10202.1.S1 reticulon 4 2.53 0.024
Bt.5073.1.S1 transmembrane emp24 protein transport domain containing 4 3.91 0.0499
Proteolysis Bt.20121.1.S1 cathepsin D 2.81 0.0164
Bt.20030.1.S1 calpain 7 2.25 0.0315
Bt.12302.1.S1 plasminogen activator, tissue 2.59 0.0203
Bt.23840.1.S1 similar to subtilisin-like proprotein convertase 4 4.35 0.0175
Bt.289.1.S1 pregnancy-associated glycoprotein 16 24.53 0.0475
Bt.3888.1.S1 protein phosphatase methylesterase 1 3.77 0.0427
Bt.393.1.S1 cathepsin B 2.18 0.0401
Bt.5462.1.S2 similar to dynein, cytoplasmic, heavy polypeptide 1 2.1 0.0349
Bt.1613.1.S1 protease, serine, 11 2.6 0.0373
Bt.7240.1.S1 leucine aminopeptidase 3 2.65 0.0344
Bt.27314.1.A1 Similar to Cgi67 serine protease 2.17 0.0427
Signal transduction Bt.5546.1.S1 guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 1 2.02 0.0267
Bt.9163.1.A1 purinergic receptor P2Y, G-protein coupled, 10 22.28 0.0249
Bt.21275.1.S1 splA/ryanodine receptor domain and SOCS box containing 3 4.90 0.0351
Bt.27421.1.S1 rho/rac guanine nucleotide exchange factor (GEF) 2 2.78 0.0303
Bt.2235.1.S2 GDP dissociation inhibitor 1 2.07 0.0416
Bt.24236.1.S1 deleted in liver cancer 1 2.43 0.0226
Bt.12694.1.S1 similar to Tumor necrosis factor receptor superfamily member 21 precursor
(TNFR-related death receptor-6) (Death receptor 6)
3.53 0.0242
Table 1. Cont.
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change
Bt.21758.1.A1 Down syndrome critical region gene 1-like 1 2.77 0.0194
Bt.20511.1.S1 similar to Ral guanine nucleotide dissociation stimulator A 2.15 0.0175
Bt.26841.1.A1 GTPase activating Rap/RanGAP domain-like 3 2.02 0.0069
Bt.2846.1.A1 similar to ras homolog gene family, member U 2.7 0.0175
Ubiquitin cycle Bt.2211.1.S1 ubiquitin-activating enzyme E1 (A1S9T and BN75 temperature sensitivity complementing) 2.19 0.0421
Bt.23266.1.S1 WW domain containing E3 ubiquitin protein ligase 2 2.26 0.0312
Bt.5408.1.A1 ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase) 3.19 0.0226
Bt.20361.1.S1 F-box and leucine-rich repeat protein 20 2.28 0.0356
Bt.13185.1 ubiquitin-like modifier activating enzyme 2 2.0 0.0209
Bt.3753.1.S1 similar to KIAA0614 protein 2.43 0.0477
Bt.7651.1.S1 ankyrin repeat and SOCS box-containing 11 2.61 0.0476
Lipid metabolic
process
Bt.4040.1.S1 platelet-activating factor acetylhydrolase, isoform Ib, gamma subunit 29 kDa 2.18 0.0119
Bt.1229.1.S1 apolipoprotein A-I 3.72 0.0138
Bt.5467.1.S1 prosaposin 4.07 0.0242
Bt.6334.1.A1 degenerative spermatocyte homolog 1, lipid desaturase 2.63 0.0203
Bt.12718.1.A1 Similar to Apolipoprotein D precursor (Apo-D) 3.75 0.0119
Bt.19709.1.S1 LAG1 homolog, ceramide synthase 2 2.71 0.016
Bt.2342.1.S1 similar to phosphatidate cytidylyltransferase 2 2.02 0.023
Bt.18340.1.A1 similar to choline/ethanolaminephosphotransferase 1 3.06 0.007
protein folding Bt.23161.2.A1 heat shock 70 kDa protein 1A 4.61 0.0275
Bt.6149.1.S1 glucose-regulated protein 170 2.3 0.0203
Bt.8686.1.S1 glucose-regulated protein 94 2.33 0.0311
Bt.514.1.S1 DnaJ (Hsp40) homolog, subfamily C, member 6 2.34 0.0242
Kinase Bt.1020.1.S1 similar to CDC-like kinase 1 2.35 0.0483
Bt.9070.2.S1 centaurin, alpha 1 2.54 0.0209
Bt.16200.1.A1 WNK lysine deficient protein kinase 2 22.8 0.0319
Bt.13980.1.A1 Creatine kinase, mitochondrial 2 2.08 0.0237
Bt.19517.1.S1 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) 2.43 0.0242
Bt.21540.1.S1 fibroblast growth factor receptor 2 2.7 0.0119
Bt.22053.1.S1 nuclear receptor binding protein 2 2.25 0.0271
Bt.22649.1.A1 focal adhesion kinase 23.82 0.0481
Bt.4413.1.S1 diacylglycerol kinase, eta 3.05 0.0324
Bt.729.1.S1 similar to TYRO3 protein tyrosine kinase 2.47 0.0119
Bt.9194.1.S1 similar to microtubule associated serine/threonine kinase 2 2.42 0.0247
Transcription or Bt.21228.1.A1 PAX interacting (with transcription-activation domain) protein 1 4.44 0.0323
Translation Bt.1078.2.S1 Nuclear factor of activated T-cells, cytoplasmic 2.74 0.044
Bt.20542.1.S1 Transcription factor jun-B 22.17 0.0261
Bt.20473.1.A1 similar to KIAA0833 protein 2.35 0.0175
Bt.2418.1.S1 Similar to KIAA0934 protein 3.04 0.0324
Bt.17848.1.S1 similar to transcriptional repressor BSR/RACK7/PRKCBP1 2.54 0.0126
Bt.19585.1.S1 similar to TFIIH basal transcription factor complex p62 subunit 2.23 0.0276
Bt.21110.1.S1 similar to neuroblastoma-amplified protein 3.94 0.0375
Bt.4804.2.A1 Cyclin-dependent kinase inhibitor 1C (p57, Kip2) 2.33 0.0455
Metabolism Bt.21917.1.S1 pyridoxal (pyridoxine, vitamin B6) phosphatase 2.76 0.0069
Bt.3162.1.S1 procollagen-proline, 2-oxoglutarate 4-dioxygenase 2.21 0.0119
Bt.23559.1.S1 similar to thiamin pyrophosphokinase 1 2.06 0.0119
Bt.15925.1.S1 epoxide hydrolase 2, cytoplasmic 2.51 0.0349
Bt.27130.1.S1 Saccharopine dehydrogenase 2.04 0.0212
Table 1. Cont.
A Transcriptome Study of BSE
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Bt.13710.1.S1 phosphatidylglycerophosphate synthase 1 3.17 0.049
Bt.21376.1.S1 STT3, subunit of the oligosaccharyltransferase complex, homolog 2.24 0.0446
Bt.20890.1.S1 amylase, alpha 2B (pancreatic) 3.38 0.0141
Bt.24210.1.S1 acyl-CoA synthetase long-chain family member 1 2.22 0.0319
Bt.1237.1.S1 A kinase (PRKA) anchor protein (yotiao) 9 2.11 0.0286
Bt.25525.1.A1 Similar to Ectonucleotide pyrophosphatase/phosphodiesterase 2 2.72 0.0186
Bt.1330.1.S1 aldo-keto reductase family 1, member B1 (aldose reductase) 2.87 0.0172
Bt.22011.1.S1 O-linked N-acetylglucosamine (GlcNAc) transferase 2.12 0.0416
Bt.5002.1.S1 glycerol-3-phosphate dehydrogenase 1 2.15 0.0447
Bt.7951.1.S1 sphingomyelin phosphodiesterase 1, acid lysosomal 2.32 0.016
Bt.9126.1.S1 similar to sterol-C5-desaturase-like 2.67 0.0441
Bt.5517.1.S1 29,39-cyclic nucleotide 39 phosphodiesterase 3.12 0.0387
Bt.24519.1.S1 similar to holocarboxylase synthetase 2.25 0.0266
Bt.25539.1.A1 similar to Heparan sulfate glucosamine 3-O-sulfotransferase 5 2.26 0.0209
Bt.3284.2.A1 Asparagine-linked glycosylation 3 homolog 22.02 0.0069
DNA or RNA Bt.22982.1.A1 reticulon 1 2.56 0.0335
binding Bt.10510.1.S1 H2A histone family, member X 2.49 0.0167
Bt.26546.1.S1 MUS81 endonuclease homolog 3.76 0.0288
Bt.22310.1.S1 ariadne homolog 2 2.28 0.0141
Bt.22356.1.S1 AT rich interactive domain 1A 2.60 0.0482
Bt.20959.1.S1 polymerase (DNA directed), alpha 2 (70 kD subunit) 23.65 0.0373
Bt.2594.1.S1 splicing factor, arginine/serine-rich 2 2.13 0.049
Bt.15534.1.S1 tubulin, alpha 1 2.26 0.0355
Bt.11182.2.S1 GC-rich sequence DNA-binding factor homolog 2.16 0.0052
Bt.27445.1.A1 similar to ELAV-like protein 3 2.25 0.0476
Bt.8206.1.S1 splicing factor, arginine/serine-rich 7, 35 kDa 2.05 0.0264
Bt.13659.1.S1 similar to pre-mRNA processing 8 protein 2.0 0.0475
Bt.13529.1.S1 similar to splicing factor 3b, subunit 1 2.1 0.0474
Bt.15754.1.S1 similar to nucleolysin TIAR 2.16 0.0141
Bt.18270.2.S1 similar to GW182 autoantigen 2.54 0.0209
Bt.19937.1.S1 similar to carboxypeptidase D 2.18 0.0203
Bt.20304.2.S1 similar to proliferation potential-related protein 2.53 0.0447
Bt.21440.1.S1 similar to DEAD box polypeptide 17 isoform p82 2.1 0.0261
Bt.28464.2.S1 splicing factor, arginine/serine-rich 4 2.92 0.0242
Protein binding Bt.10723.1.S1 similar to RING finger protein 13 2.92 0.0129
Bt.11149.1.S1 vimentin 2.38 0.0141
Bt.20175.1.S1 HLA-B associated transcript 5 5.0 0.0175
Bt.26104.1.A1 WAS protein family, member 1 2.17 0.0272
Bt.13983.1.A1 metadherin 2.01 0.0399
Bt.22603.1.S1 leucine rich repeat transmembrane neuronal 1 22.56 0.036
Bt.12039.1.S1 protein arginine methyltransferase 2 2.70 0.04
Bt.18229.1.A1 similar to partner and localizer of BRCA2 4.22 0.0469
Bt.12825.1.S1 similar to Actin, aortic smooth muscle (Alpha-actin-2) 4.54 0.049
Bt.1690.1.S1 similar to goliath protein 2.05 0.0318
Bt.1766.1.S1 actin related protein 2/3 complex subunit 1A 2.16 0.0467
Bt.29710.1.A1 tight junction protein 3 22.71 0.04
Membrane Bt.10179.1.S1 liprin beta1 3.77 0.0375
protein Bt.1076.1.S1 arylsulfatase A 2.20 0.0203
Table 1. Cont.
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infection status. However, it would not be practical to apply all 409
or 205 probe sets as biomarkers to represent BSE. A group of 10
genes were sought to represent BSE from these 230 genes listed in
Table 1. Initially, the search was carried out using genes associated
with prion diseases (10 genes), ER stress (10 genes), the largest fold
changes (10 genes) or the smallest p values (10 genes) separately
but the sensitivity and specificity of prediction were low. When
these 40 genes were combined and10 genes were selected from
them by comparing the expression levels of individual samples
from both this study (clinical BSE, n= 14; control, n = 12) and the
time course study (clinical BSE, n= 3; control, n = 3), only two
groups were produced (Figure 5a). Group A contained all the
clinical BSE samples from both studies and group B all the
negatives with only three exceptions: P19, Neg2 and Neg3. The
sensitivity of these biomarkers was 94% (16/17) and the specificity
was 87% (13/15).
Gene ID Gene Nams Fold p-value
change
Bt.5447.1.S1 natriuretic peptide receptor B/guanylate cyclase B 2.07 0.0105
Bt.13265.1.A1 similar to plasmolipin 2.77 0.0165
Bt.23589.2.S1 signal sequence receptor, alpha 2.19 0.0418
Bt.22858.1.S1 uroplakin 3B 22.3 0.0335
Bt.5636.1.S1 similar to Exocyst complex component 1 2.07 0.0307
Bt.13940.1.S1 similar to CDC91 cell division cycle 91-like 1 2.39 0.0206
Bt.14205.1.S1 LMBR1 domain containing 1 2.57 0.0119
Bt.3625.1.S1 transmembrane protein 85 2.16 0.0414
Bt.15878.1.S1 similar to LanC-like protein 1 (40 kDa erythrocyte membrane protein) 3.24 0.0097
Bt.20013.1.S1 similar to ELOVL family member 7, elongation of long chain fatty acids 2.5 0.0138
Bt.20219.1.S1 similar to phosphatidyl inositol glycan class T 2.37 0.0385
Bt.6405.1.S1 myelin basic protein 4.85 0.0303
Bt.22251.1.A1 similar to chemokine-like factor super family 4 3.51 0.0385
Bt.23354.1.S1 similar to epoxide hydrolase 1 2.63 0.0139
Bt.5333.1.S1 cysteine-rich with EGF-like domains 1 2.31 0.0399
Bt.2606.1.S1 lysosomal-associated membrane protein 2 3.17 0.0151
Bt.3904.1.S1 thioredoxin-related transmembrane protein 2 2.99 0.0399
Bt.488.1.S2 phospholipase A2 receptor 1, 180 kDa 2.26 0.0309
Bt.24941.1.S1 abhydrolase domain containing 3 2.49 0.0242
Bt.7172.1.S1 myelin oligodendrocyte glycoprotein 3.45 0.0052
Bt.7677.1.S1 transmembrane protein 59-like 3.7 0.0475
Bt.8787.1.S1 adiponectin receptor-1 2.6 0.0067
Bt.3410.1.S1 synaptogyrin 2 2.48 0.0476
Endosome Bt.11002.1.S1 OCIA domain containing 1 24.92 0.0299
Bt.11329.1.S1 vacuolar protein sorting 11 homolog 2.41 0.0385
Bt.22508.1.S1 PRA1 domain family, member 2 3.09 0.0483
Others Bt.12906.1.S1 similar to Gelsolin precursor (Actin-depolymerizing factor) 2.59 0.0209
Bt.13321.1.S1 centrosome and spindle pole associated protein 1 2.26 0.0304
Bt.14136.1.A1 similar to Endonuclease domain containing 1 3.52 0.0386
Bt.21008.1.S1 similar to FGFR-like protein 2.76 0.0416
Bt.22605.1.A1 zinc finger, CW type with PWWP domain 1 2.08 0.0178
Bt.23348.2.S1 zyxin 3.83 0.0385
Bt.26865.1.S1 Myosin head domain containing 1 5.75 0.0485
Bt.1409.1.S1 tubulin polymerization-promoting protein family member 3 2.04 0.0236
Bt.4386.1.S1 synapsin I 4.24 0.0482
Bt.1088.1.S1 GTPase, IMAP family member 7 0.32 0.0419
Bt.6989.1.S1 responsive to centrifugal force and shear 2.79 0.007
Bt.28035.1.S1 fat storage-inducing transmembrane protein 2 3.64 0.0367
Gene functions are defined largely according to Affymetrix GO biological process term or GO molecular function term.
*: genes associated with the endoplasmic reticulum in bold.
doi:10.1371/journal.pone.0014207.t001
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These 10 genes above were then used to classify the preclinical
samples from the time course study with clustering analysis. The
clustering analysis produced two groups: three negatives and three
6 mpi samples being one group and three positives and 45 mpi
samples being the other with 100% (5/5) sensitivity and 100% (6/
6) specificity (Figure 5b). Therefore, the results of these analyses
suggest that these 10 genes might be used to represent the patterns
of BSE gene expression at the terminal stages of BSE.
Discussion
In this study, 230 genes were found to be differentially regulated
between BSE field cases and controls (Table 1). These genes
belong to many functional groups from apoptosis to transport.
Seventeen genes were associated with the ER and 10 of them may
be involved in stress related situations, especially up-regulation of
ER chaperones Grp94 and Grp170 as they are ER stress markers.
Since ER stress triggers the UPR [37,38,39], the level of protein
expression of Grp78, another ER stress marker, was increased in
BSE. Up-regulation of Grp78, Grp94 and Grp170 is induced by
ER stress response transcription factors XBP1 and ATF6 as all
three of them have an ER stress response element (ERSE) in their
regulatory regions [36]. These analyses suggest the presence of ER
stress and the activation of the UPR in the disease process of BSE.
This is in agreement with increasing evidence of the involvement
of ER stress in prion diseases [40,41,42]. In this study only changes
in gene and protein expression of these chaperones were measured
to indicate activation of the UPR. There are other methods to
measure the induction of the UPR as many proteins are activated
or inactivated through phosphorylation cascade in the UPR
Figure 1. Condition tree of clustering analysis to test tissue sample consistence. The analysis was performed by GeneSpring using 409
differential regulated probe sets on Bovine GeneChips. The similarity was measured using the Spearman correlation with value 1 for separation ratio
and value 0.001 for minimum distance in merge similar branches. N: negative controls and P: clinical BSE samples. Each of coloured bars represents a
gene and the colour represents the levels of expression. The relative levels of expression are displayed in different colours: Red: 5; orange: 2; yellow: 1;
dark yellow: 0.7; dark blue: 0.4; blue: 0.1.
doi:10.1371/journal.pone.0014207.g001
Figure 2. Western blotting of ER stress related proteins Grp78
and Chop. The relative quantity was the mean values of three controls
(N5, N21 and N25) and three clinical BSE samples (P6, P10 and P14). b-
Actin was used for normalization. *: p = 0.042 (student’s t-test).
doi:10.1371/journal.pone.0014207.g002
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signalling pathways. For example, the release of Grp78 bound to
PERK triggers autophosphorylation of PERK which in turn
phosphorylates elf2a to attenuate protein translation [36].
To cope with accumulation of misfolded proteins, ER stress
induces ER associated protein degradation I (ERAD I, ubiquitin/
proteasome) [43] and ERAD II (autophagy/lysosome) [44],
possibly through the UPR. ERAD I is closely linked to the ER
quality control system [45] as unfolded or misfolded proteins are
targeted for degradation after the failed attempt of folding by ER
chaperones. In BSE, ubiquitin-activating enzyme E1 (UBE1) and
three E3 ligases: WW domain containing E3 ubiquitin protein
ligase 2 [46], ariadne homolog 2 [47] and ubiquitin carboxyl-
terminal esterase L1 [48] were found to be up-regulated (Table 1).
Recently, the E3 ligase HECTD2 has been identified as genetically
associated with vCJD and kuru [49].
ERAD II is also known as autophagy. It is a pathway of self-
degradation of cellular components in which autophagosomes
sequester organelles or protein aggregates and fuse with lysosomes
for degradation. When the production of misfolded proteins
exceeds the capacity of ER chaperones and ERAD I, misfolded
and aggregated proteins are targeted by the aggresome-autophagy
pathway [50]. In BSE, up-regulation of several genes (Table 1)
suggests that this pathway might be induced. In the lysosome, both
cathepsin B and D (lysosomal hydroases) were up-regulated [44].
On the membrane of the lysosome, the increased levels of
lysosomal-associated membrane protein 2 (LAMP2) suggest
autophagy initiation [51]. In the cytosol, there were also several
up-regulated genes related to ERAD II, such as ubiquitin
carboxyl-terminal esterase L1 (aggresome initiation in proteasome
inhibition) [48], sphingomyelin phosphodiesterase 1, acid lysosomal
(SMPD1; autophagy promotion) [52] and vimentin (cytoskeleton)
[14] (Table 1). This association between ERAD II and BSE has
been shown in both mice and cattle [53,54].
In this study, the analyses suggest that ER stress might be
involved in BSE pathogenesis and that the UPR, ERAD I and II
might all be activated in a concerted effort to rid the cell of
harmful PrPSc. The question, therefore, is how much these ER
related pathogenic events contribute to fatal prion diseases in
general. When the GPI anchor of the PrP protein is removed, the
transgenic mice infected with scrapie, also a prion disease, can
survive up to 400–600 days post infection (dpi) without clinical
scrapie, while the wild type controls develop clinical signs within
140–160 dpi [55]. Some animals with this anchorless PrP have up
to 40% more PrPSc than clinically sick controls. The results
indicate that infectivity (PrPSc accumulation) and toxicity can be
uncoupled. One model to explain it is intra neuronal generation of
a toxic intermediate [32]. Here we offer another explanation of
prion neurotoxicity using ER stress. The reason for PrPSc
accumulation in the ER is because the ER quality control system
senses the misfolded forms of PrP and ER chaperones retain them
in the ER for folding or degradation by ERAD I. PrPSc is protease
resistant so that the rate of removing the misfolded protein is slow;
while more and more PrPC converts to PrPSc. Eventually, PrPSc
Figure 3. Clustering analysis of sample status in the BSE field
case study. The analysis was performed by GeneSpring using 205
differential regulated probe sets generated from the time course study
[11]. The similarity was measured using the spearman correlation. N:
BSE negative controls; P: clinical BSE samples.
doi:10.1371/journal.pone.0014207.g003
Figure 4. Clustering analysis of sample status in the BSE time
course study. The analysis was performed by GeneSpring using 409
differential regulated probe sets generated from this study and the
samples were from the BSE time course study [11]. The similarity was
measured using the spearman correlation. Neg: BSE negative controls;
Pos: clinical BSE samples and m: months post inoculation. (a): the
samples were grouped to the time point; (b): the individual samples of
negative controls, clinical BSE samples, 6 mpi and 45 mpi.
doi:10.1371/journal.pone.0014207.g004
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accumulation causes ER stress and the subsequent activation of
the UPR and ERAD I and II. Prolonged ER stress leads to cell
death [45,56]. Hence, ER stress related responses might be the
major source of prion toxicity. What happens when misfolded
PrPSc bypasses the ER quality control? There are lines of evidence
that the anchorless prion protein is not detected by the ER quality
control system [57,58]. As the anchorless PrPSc can pass the ER
efficiently, there is no toxicity to cause clinical scrapie. Since the
cell is not under ER stress, the ERAD pathways are not activated.
As a result, more PrPSc accumulates in the brain of transgenic
mice with anchorless PrP than in the brain of the wild type
controls.
Both the current field case study and the previous time course
study were carried out with brainstem tissues infected with BSE
[11]. Although these two sets of samples differed in age, in
infectious dose and in stages of disease development, many
differentially regulated genes were expected to be shared between
these two studies. Nonetheless, when the two gene lists were
compared, there were only two genes overlapping. However, the
profiles generated from one study could be used to predict the
sample status of the other study as biomarkers, suggesting that
there were some underlying links between these two gene lists
(Figures 3 and 4). One possible explanation is that there are more
differentially regulated genes than those identified by the analytical
method. In order to define a gene list that is relevant with a
condition or a disease within a study, the p value is often set at 0.05
or less. However, by doing so, much of the coverage is lost and
many differentially regulated genes are not considered. In order to
make the list more manageable, an additional 2 fold change filter
was introduced to reduce the number of probe sets to 409. If the
fold change filter had not been introduced and the p value had
been set at 0.1, the number of probe sets would have been 1604.
By definition, only 160 of them were selected randomly and the
rest of 1446 probe sets should be truly differentially regulated. The
remaining 1037 (1446-409) probe sets were not analyzed. Figure 6
provides a simple graphical model for this situation. The small
inner circles (stringent settings) overlap only marginally. If all
differentially regulated genes had been considered (large circles),
there would have been many genes shared by these two studies
and that is the most likely reason why the profiles from one study
could be used to predict sample status from the other study. In
recent years, there have been many publications on gene
expression analyses of prion diseases. It is a surprise that relatively
few differentially regulated genes are shared between these studies
[11,12,13,16,59,60]. However, the explanation above for the BSE
studies may also apply to gene expression studies of prion diseases
in general.
Considerable efforts have been made to find biomarkers for the
prion diseases, especially in the early stage of the incubation
period. To date, the detection of PrPres is still the only reliable
method. There are some reported potential biomarkers for the
disease such as 14-3-3 protein [61], galectin-3 [62], SCRG1 [63],
clusterin [64] and cystatin C [65]. However, none of them has
been developed for routine diagnosis. One of the reasons may be
the natural variation for the single marker within a population.
Clustering analysis suggested that a prediction could be made by
comparing the gene expression profiles of a sample with those of
known BSE positive and negative samples. The analysis also
showed a proof of principle that a prediction for a given sample
could be made with high sensitivity (94%) and specificity (87%)
using just 10 genes as biomarkers although the tissues used in this
study were from the brainstem which may not be suitable for
diagnose. These ten gene markers might represent the diseased
state better than any single markers as they might allow some
variations in expression. In Huntington’s disease, gene expression
profiling of blood reveals a subset of 12 up-regulated mRNAs
Figure 5. Clustering analysis of possible biomarkers for BSE. The analysis was performed by GeneSpring using 10 differential regulated genes
generated from this study. The similarity was measured using the change correlation with value 1 for separation ratio and value 0.001 for minimum
distance in merge similar branches. (a), All samples. N: BSE negative controls and P: clinical BSE samples in this study. Pos: clinical BSE and Neg: the
negatives from the BSE time course study [11]. (b), samples from the BSE time course study. m: months post inoculation. Each of coloured bars
represents a gene and colours represent the levels of expression. The relative levels of expression are displayed in different colours: Red: 5; orange: 2;
yellow: 1; dark yellow: 0.7; dark blue: 0.4; blue: 0.1.
doi:10.1371/journal.pone.0014207.g005
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which have been shown to be able to distinguish controls,
presymptomatic Huntington’s disease gene carriers and symptom-
atic Huntington’s disease patients [66].
In conclusion, gene expression analysis suggests that BSE
infection caused ER stress and the UPR, ERAD I and II might be
induced in response to ER stress. Clustering analysis showed that
the differentially regulated genes could be used to predict infection
status. Ten genes were selected to represent gene expression state
in BSE, which might eventually be used as biomarkers.
Materials and Methods
Tissue samples
Brainstem tissues from 100 confirmed cases of BSE in cattle
were supplied by the TSE archive at the Veterinary Laboratories
Agency, UK. The animals were females, between 4 and 10 years
old that had been diagnosed clinically and killed on farm. The
major breed was Holstein/Friesian and other breeds were:
Limousin Cross, Guernsey, Hereford Cross and Brown Swiss.
The negative controls (100 brainstem tissue samples) were from
LGC Forensics (Queens Road, Teddington, Middlesex, TW11
0LY, UK) and were comparable in breed, sex and age with the
naturally infected BSE samples. Since all samples were from the
Archives, approval from the Ethics Committee was not necessary.
Microarrays analysis
The preparations of samples and reagents were carried out
according to the Affymetrix GeneChip Expression Analysis
manual and as described in the previous study [11]. The RNA
samples were resolved by 1% agarose gels and selected according
to the integrity of ribosomal RNA bands. Since the tissues used in
this study were from cattle naturally infected with BSE (field cases),
the quality of RNA was generally poor. From 100 cases each, the
best quality RNA samples, 12 controls and 14 BSE infected, were
selected for microarray analysis with Affymetrix GeneChip Bovine
Genome Arrays. The raw data were first imported into the
Affymetrix GeneChip operating software version 1.4. All array
data were MIAME compliant and the raw data were deposited in
ArrayExpress with the accession number: E-MTAB-302. After
initial analysis, the pivot formatted data were further analysed with
the GeneSpring version 7 software (Silicon Genetics). The data
were normalized in three steps: 1. Data transformation set
measurements less than 0.01 to 0.01; 2. Each measurement was
divided by the 50.0th percentile of all measurements in that
sample; 3. Each measurement for each gene in test samples was
divided by the median of that gene’s measurements in the
corresponding control samples. The value for each gene was
divided by the median of its measurements in all samples. If the
median of the raw values was below 10 then each measurement for
that gene was divided by 10. If the numerator was above 10, the
measurement was discarded. These steps were the default settings
for the GeneSpring package.
Two filters were used to find differently regulated genes: 2 fold
change and the one way ANOVA statistical analysis with the
parameters of 0.05 for p-value cutoff, multiple testing correction
and Student-Newman-Keuls for the post hoc tests, without assume
variances equal for the parametric test.
Western blotting
Cell-free extracts (60 mg protein) were loaded on 12% 1-D SDS
PAGE (Invitrogen) and resolved proteins from several mini-gels
were transferred to the same PVDF membrane (Millipore) so that
one set of samples was used to monitor protein loading using b-
Actin. The blots were immuno-stained with mouse monoclonal
anti-b-Actin IgG (Santa Cruz Biotech), rabbit polyclonal anti-
Grp78 (US Biological) and rabbit polyclonal anti-Chop (BioLe-
gend). The protein bands were visualized by using secondary
antibodies, alkaline phosphatase conjugated IgGs (anti-mouse,
Santa Cruz Biotech; anti-rabbit, Sigma) and the ECL developer
kit (Amersham). The images were captured by Fluor-S Multi-
Imager (Bio-Rad) and the protein bands were quantified by the
Quantity One software (Bio-Rad).
Quantitative PCR
The RNA samples were treated with the DNA freeTM kit
(Ambion) for 1 h at 37uC to remove any trace of DNA. The
treated RNA was then used as a template for cDNA synthesis with
the TaqMan reverse transcription kit (Applied Biosystems). The
real time PCR was carried out by denaturing at 95uC for 15 s,
annealing at 50uC for 2 min and extension at 60uC for 1 min for
40 cycles using an ABI Prism 7700 Sequencing Detector. The
GAPDH gene was used as an internal control to normalize the
expression levels of target mRNA. The primer sets were chosen by
the Primer Express 1.5 for TaqMan software. The sequences of
the primer sets were as following: for CD47, 59-TCC ATT AAC
GAT TCT AAA TAA AGG AAA CT, 59-TGC TAT GGA AAA
AAG CCC CC and the probe, FAM-59-TGG TGT TGC TAT
GCG TGA GAT CCT CTC C; for DNAJ, 59-TCT GTG AAA
ATA AAG CAG GAG TGA A, 59- AGT GAG AAA CAG CCA
AAA TAC TGA AC and the probe, FAM-59- CCT TTG CAG
ACT TCA GAC TGG TTG GAT TTC; for KCNB2, 59- TGA
TGA CTT CTT AGA GCT CCA GGG, 59-CAA GCA GTT
TGG GCT GGA GT and the probe, FAM-59-AGG AGG CCG
GAC AAG CAG GCA; for HS70, 59- GGA CTT TGG TCT
TGC CCT ATA TTT AC, 59-CAC ACT CAC TAT AAC ATA
CAG AAA TAA CA AAA A and the probe, FAM-59-TGT GAT
Figure 6. A model to explain the relationship between two BSE
gene expression studies. The larger circles represent all differentially
genes; while the inner circles represent differentially regulated genes
listed in the studies with p value being less than 0.05. The blue circles:
the time course study. The red circles: the field case study.
doi:10.1371/journal.pone.0014207.g006
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GTG TCA GTT TGT TCT ATG ATA AGG TTG TAA TCT
C; for TNFRSF5, 59-CGT GGA GAC GAT TGA TCC G, 59-
AGC ATA AGG TCT CTT GCA CCG and the probe, FAM-59-
AGG ATT TTC CCG GCC CCC ACC.
Supporting Information
Figure S1 Validation of microarray data by RT-PCR. 1 and 2:
CD47; 3 and 4: DNAJ; 5 and 6: KCNB; 7 and 8: HS70; 9 and 10:
TNFRSF5. The values of gene expression are listed at the top for
comparison. No fill: negative controls; Grey: clinical BSE.
Found at: doi:10.1371/journal.pone.0014207.s001 (0.24 MB TIF)
Table S1 Unannotated probe sets in the BSE field case study
Found at: doi:10.1371/journal.pone.0014207.s002 (0.18 MB
DOC)
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